A Phase 2 Study of Oral MKC-1 in Patients With Ovarian or Endometrial Cancer

Phase 2 Completed 44 enrolled CASI pharmaceuticals, Inc.

Non-randomizedParallel-groupOpen-labelTreatment

Summary

Patients will be treated with MKC-1, twice daily for 14 consecutive days every four weeks (a cycle of MKC-1 chemotherapy), until disease progression or unacceptable toxicities. Patients will be stratified to Arm A (ovarian cancer) or Arm B (endometrial cancer), and will receive identical treatment regimens.

Timeline

Start: 2008-01
Primary completion: 2011-06
Completion: 2012-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	MKC-1	Small molecule	125 mg/m2	Oral

A Phase 2 Study of Oral MKC-1 in Patients With Ovarian or Endometrial Cancer

Summary

Timeline

Drugs

Indications